Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: NYU Langone’s Laura and Isaac Perlmutter Cancer Center, Hospital Universitario Fundación Jiménez Díaz, Institut Gustave Roussy, Austin Hospital, Austin Health, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Bergonié, University of Siena, City Of Hope National Medical Center, City of Hope, The Netherlands Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), GlaxoSmithKline (United States), Institut Curie
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3167686988